Syros Pharmaceuticals Inc (NASDAQ:SYRS)‘s stock had its “buy” rating restated by investment analysts at Piper Jaffray Cos. in a research note issued on Thursday. They currently have a $20.00 price target on the stock. Piper Jaffray Cos.’s price objective indicates a potential upside of 50.94% from the stock’s previous close.

SYRS has been the topic of a number of other reports. HC Wainwright reissued a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a research note on Friday, September 9th. Wedbush initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $18.00 target price on the stock. Cowen and Company initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating on the stock. JMP Securities initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $22.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $17.50.

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded up 0.60% during mid-day trading on Thursday, hitting $13.33. The company had a trading volume of 900 shares. Syros Pharmaceuticals has a 52-week low of $8.16 and a 52-week high of $21.50. The firm has a 50-day moving average price of $11.67 and a 200 day moving average price of $12.69. The firm’s market capitalization is $311.58 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/syros-pharmaceuticals-inc-syrs-earns-buy-rating-from-piper-jaffray-cos.html

In other news, Director Robert Nelsen purchased 400,000 shares of the business’s stock in a transaction dated Wednesday, July 6th. The stock was acquired at an average price of $12.50 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Redmile Group, Llc purchased 432,746 shares of the business’s stock in a transaction dated Wednesday, July 6th. The shares were purchased at an average price of $12.50 per share, with a total value of $5,409,325.00. The disclosure for this purchase can be found here.

Several hedge funds have recently made changes to their positions in the company. Redmile Group LLC purchased a new stake in shares of Syros Pharmaceuticals during the second quarter worth about $15,058,000. Flagship Ventures Fund IV General Partner LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at $87,241,000. Weiss Multi Strategy Advisers LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at $832,000. Deerfield Management Co. bought a new stake in Syros Pharmaceuticals during the second quarter valued at $38,028,000. Finally, Aisling Capital LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at $16,490,000.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.